Q BioMed Inc () CEO Denis Corin tells Proactive the group will begin production MAN-19, a clinical grade therapeutic intended to treat complications caused by the coronavirus.
Corin says the Phase 1 clinical trial, which will be conducted with technology partner Mannin Research, is slated to begin patient enrollment in February 2021.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE